Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1 - Cyclin D3 colocalization in tumor cells

Blood

Volumn 94, Issue 2, 1999, Pages 765-772

  Sánchez Beato, Margarita ^a   Camacho, Francisca I ^a   Martínez Montero, Juan C ^a   Sáez, Ana I ^a   Villuendas, Raquel ^a   Sánchez Verde, Lydia ^a   García, Juan F ^a   Piris, Miguel A ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27;

ARTICLE; B CELL LYMPHOMA; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

EID: 0344731443     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.2.765     Document Type: Article

References (34)

1. Graña X, Reddy EP: Cell cycle control in mammalian cells: Role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11:211, 1995
2. Hirama T, Koeffler HP: Role of cyclin-dependent kinase inhibitors in the development of cancer. Blood 86:841, 1995
3. Sherr CJ: Cancer cell cycles. Science 274: 1672, 1996
4. KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59, 1994
5. Reynisdóttir I, Polyak K, Iavarone A, Massagué J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-$. Genes Dev 9:1831, 1995
6. Soos TJ, Kiyokawa H, Van JS, Rubin MS, Giordano A, DeBlasio A, Bottega S, Wong B, Mendelsohn J, Koff A: Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ 7:135, 1996
7. Cheng M, Sexl V, Sherr CJ, Roussel MF: Assembly of cyclin D-dependent kinase and titration of p27KIP1 regulated by mitogen-activated protein kinase kinase (MEK!). Proc Natl Acad Sci USA 95:1091, 1998
8. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p16/CDKN2 in primary tumours. Nat Genet 11:210, 1995
9. Pollock PM, Pearson JV, Hayward NK: Compilation of somatic mutations of the CDKN2 gene in human cancers: Non-random distribution of base substitutions. Genes Chromosomes Cancer 15:77, 1996
10. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1:686, 1995
11. Shiohara M, El-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, Vogelstein B, Koeffler HP: Absence of Waf1 mutations in a variety of human malignancies. Blood 84:3781, 1994
12. KIP1 in human malignancies. Cancer Res 55:2266, 1995
13. KIP1 gene in Non-Hodgkin's Lymphomas and adult T-cell leukemia/lymphoma. Blood 86:1924, 1995
14. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 55:1206, 1995
15. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW, Vogesltein B: WAF1, a potential mediator of p53 tumour suppression. Cell 75:817, 1993
16. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteosome-dependent degradation of cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 3:231, 1997
17. Sánchez-Beato M, Sáez AI, Martínez-Montero JC, Mateo MS, Sánchez-Verde L, Villuendas R, Troncone G, Piris MA: Cyclin-Dependent Kinase Inhibitor p27KIP1 in Lymphoid tissue. P27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol 151:151, 1997
18. Quintanilla-Martínez L, Thieblemont C, Fend F, Kumar S, Pinyol M, Campo E, Jaffe ES, Raffeld M: Mantle Cell Lymphoma lack expression of p27KIP1, a Cyclin-Dependent Kinase Inhibitor. Am J Pathol 153:175, 1998
19. Kip1 protein: Prognostic implications in primary breast cancer. Nature Med 3:227, 1997
20. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 3:222, 1997
21. Sáez Al, Sánchez E, Sánchez-Beato M, Cruz MA, Chacon I, Muñoz E, Camacho FI, Martínez-Montero JC, Mollejo M, García JF, Piris MA: P27KIP1 is abnormally expressed in Diffuse Large B-cell Lymphomas, and is associated with an adverse clinical outcome. Br J Cancer (in press)
22. Sgambato A, Zhang YJ, Arber N, Hibshoosh H, Doki Y, Ciaparrone M, Santella RM, Cittadini A, Weinstein IB: Deregulated expression of p27kip1 in human Breast Cancers. Clinical Cancer Res 3:1879, 1997
23. Fredersdorf S, Burns J, Milne AM, Packham G. Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X: High level expression of p27KIP1 and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27KIP1 and degree of malignancy in human breast and colorectal cancers. Cancer Res 94:6380, 1997
24. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H, Weinstein IB: Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res 58:114, 1998
25. Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum-Cymbalista F: Prognostic significance of the cell cycle inhibitor p27KIP1 in Chronic B-cell lymphocytic leukemia. Blood 91:4694, 1998
26. Doki Y, Imoto M, Han EK-H, Sgambato A, Weinstein IB: Increased expression of the p27KIP1 protein in human esophageal cancer cell lines that over-express cyclin D1. Carcinogenesis, 18:1139, 1997
27. Lammie GA, Smith R, Silver J, Brookes S, Dickson C, Peters G: Proviral insertions near cyclin D1 in mouse lymphomas: a parallel for BCL1 translocations in B-cell neoplasms. Oncogene 7:2381, 1992
28. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermenlink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 84:1361, 1994
29. Bartkova J, Zemanova M, Bartek J: Abundance and subcellular localization of Cyclin D3 in Human Tumors. Int J Cancer 65:323, 1996
30. Villuendas R, Sánchez-Beato M, Martinez JC, Sáez AI, Martinez-Delgado B, García JF, Mateo MS, Benitez J, Martinez P, Piris MA: Loss of p16/INK4 protein expression in non-Hodgkin's lymphomas is a finding associated with tumoral progression. Inactivation of the CDKN2 gene is more frequently due to the novo methylation. Am J Pathol 153:887, 1998
31. Ott MM, Bartkova J, Bartek J, Dürr A, Fischer L, Ott G, Müller-Hermelink HK, Kreipe H: Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. Blood 90:3154, 1997
32. Doglioni C, Chiarelli C, Macri E, Dei Tos AP, Meggiolaro E, Dalla Palma P, Barbareschi M: Cyclin D3 expression in Normal, reactive and neoplastic tissues. J Pathol 185:159, 1998
33. Blain SW, Montalvo E, Massagué J: Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with Cyclin A-Cdk2 and cyclin D2-Cdk4. J Biol Chem 272:25863, 1997
34. Quintanilla-Martínez L, Davies-Hill T, Sorbara L, Jaffe ES, Raffeld M: Loss of detectable p27 protein expression in Mantle Cell Lymphomas (MCL) is a result of its sequestration by cyclin D1: Implications for pathogenesis. Blood 92:10, 1999 (suppl 1:314a)